Menin inhibitor + venetoclax + azacitidine
Combining the newest leukaemia drug class with the venetoclax backbone is producing remission rates in frontline NPM1 and KMT2A leukaemia that single agents never reached.
KOMET-007 (ziftomenib) and BEAT-AML/SAVE (revumenib) triplets report composite remission rates above 80% in newly diagnosed NPM1-mutant or KMT2Ar AML in early cohorts; phase 3 registration trials are underway. Differentiation syndrome and cytopenias are the management challenge.
Revumenib proved that a transcriptional dependency, rather than a kinase, can be drugged in leukaemia, opening treatment for two genetic subgroups that together cover roughly a third of AML plus most infant ALL. It is now approved and is being combined with venetoclax-azacitidine and intensive chemotherapy in front-line trials. Single-agent remissions are often short without transplant.
VIALE-A turned a palliative regimen into one that produces remission in two-thirds of older AML patients and is now the reference treatment for anyone not fit for intensive chemotherapy. It shifted the field towards lower-intensity targeted combinations and opened the door to adding FLT3, IDH and menin inhibitors to the backbone. Cure remains uncommon and most patients relapse within two years.
Pages like this
not linked directly; found by shared links- TrialAUGMENT-101
Shares NPM1 mutation, AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, KMT2A (MLL) rearrangement, Revumenib.
- TrialKOMET-001
Shares NPM1 mutation, Ziftomenib, Menin, Acute myeloid leukaemia.
- CompanyKura Oncology
Shares AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Ziftomenib, Acute myeloid leukaemia.
- IdeaMenin inhibitors for infant KMT2A-rearranged ALL
Shares KMT2A (MLL) rearrangement, Ziftomenib, Revumenib, Menin.
- CompanySyndax Pharmaceuticals
Shares AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Acute myeloid leukaemia.
- PairingVenetoclax + hypomethylating agent
Shares VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy, Azacitidine, Venetoclax, Acute myeloid leukaemia.
- TrialVIALE-A
Shares VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy, Azacitidine, Venetoclax, Acute myeloid leukaemia.
- Key paperAGILE: ivosidenib plus azacitidine for newly diagnosed IDH1-mutated AML in patients unfit for intensive chemotherapy
Shares VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy, Azacitidine, Venetoclax, Acute myeloid leukaemia.